An interventional study of CAPA-IVM and In-House CAPA-IVM Pre-Maturation Medium in Infertility (IVF Patients), Infertility and Infertility Female, sponsored by New Hope Fertility Center. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years to 38 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by New Hope Fertility Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Infertility, Female with a site in United States — 22 open to participants now, 24 under way, none of them phase 3. Infertility, Female · United States.
Among the 65 studies in Infertility, Female with a site in United States, this one is the 33rd largest by planned enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2026, is one of 30 with no phase, reaches primary completion later than 12 of the 23 other live ones, and was the 65th registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →22 of the 65 studies in Infertility, Female with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
Shady Grove Fertility Reproductive Science Center · Sites in United States
Women only
University of Southern California · Sites in United States
Ages 18–44 · Women only
University of Colorado, Denver · Sites in United States
Ages 18–38 · Women only · Healthy volunteers
Center for Reproductive Health & Gynecology · Sites in United States, Mexico
Ages 18–55 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 38 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4 · Phase 4 6
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 50 across the 47 interventional studies, 175 across the 18 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 65 have an industry lead sponsor. The 10 most frequent:
New Hope Fertility Center is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
New Hope Fertility Center has 1 study filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
5 of the studies in Infertility, Female with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06434233Johns Hopkins UniversityOpioid Use After Laparoscopic Salpingectomy | 2026-11 |
| NCT05997407Virginia Polytechnic Institute and State UniversityThe Effect of a Mindset Management Approach on Stress Levels in Women With Infertility | 2026-12 |
| NCT07858435New Hope Fertility CenterIntra-ovarian CAPA-IVM vs Standard IVM | 2027-03 |
| NCT06686537University of Colorado, DenverConvergent Mechanisms Underlying Reprometabolic Syndrome in Women | 2027-10 |
| NCT04628507Genomic Prediction Inc.Cell Free Preimplantation Genetic Testing | 2027-11-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 65 studies in Infertility, Female with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective study compares two approaches to obtaining mature oocytes for fertility treatment within the same participant. Immature oocytes are first retrieved from the right ovary and matured in the laboratory using a two-step biphasic capacitation in vitro maturation method (CAPA-IVM). Beginning on Day 5 of the same menstrual cycle, the left ovary undergoes minimal controlled ovarian stimulation followed by routine oocyte retrieval and IVF/ICSI.
The primary objective is to evaluate the maturation of CAPA-IVM oocytes to the metaphase II (MII) stage and compare reproductive laboratory outcomes between the CAPA-IVM and minimal-stimulation OS-IVF approaches. Secondary outcomes include fertilization, embryo development, blastocyst formation, embryo quality, pregnancy and live birth outcomes, and safety.
This is a prospective, within-patient comparative study in women undergoing fertility treatment. Each participant serves as her own internal control. At the Day 3 baseline visit, the right ovary is assigned to the CAPA-IVM approach and the left ovary is assigned to minimal controlled ovarian stimulation followed by IVF/ICSI. Both approaches are performed within the same menstrual cycle.
For the CAPA-IVM arm, immature oocytes are retrieved from the right ovary beginning on or after menstrual cycle Day 3, before ovarian stimulation is initiated. The right ovary is not stimulated and does not receive an ovulation trigger before oocyte collection. Retrieved cumulus-oocyte complexes are handled separately, and immature oocytes at the germinal vesicle (GV) or metaphase I (MI) stage undergo a biphasic CAPA-IVM process consisting of an initial pre-maturation/capacitation phase followed by transfer to maturation conditions and assessment for development to the metaphase II (MII) stage.
After completion of right-ovary aspiration, minimal controlled ovarian stimulation of the left ovary begins on Day 5. The protocol uses clomiphene citrate for approximately 9 days and follitropin beta for approximately 3 days, with ultrasound and/or hormonal monitoring. Final oocyte maturation is initiated with leuprolide acetate as a GnRH-agonist trigger, followed by routine oocyte retrieval from the left ovary.
Mature oocytes obtained from both approaches may undergo ICSI according to New Hope Fertility Center clinical practice. Oocyte assessment and selection for ICSI, ICSI itself, and standard embryo culture are considered clinical procedures; the research-specific component is the CAPA-IVM maturation approach and the within-patient comparison of outcomes according to ovary of origin. Oocytes and embryos are tracked separately to maintain traceability throughout fertilization, embryo culture, and subsequent clinical outcomes.
The primary endpoint is the proportion of immature CAPA-IVM oocytes that mature to the MII stage. Secondary endpoints include fertilization rate, cleavage, blastocyst formation, high-quality blastocyst formation, implantation, clinical pregnancy, ongoing pregnancy, live birth, neonatal outcomes, and safety outcomes including procedure-related complications and ovarian reserve measures.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
This study's planned enrollment of 20 is below the median of 100 across 378 interventional studies indexed under Infertility, Female.
Browse Infertility, Female studies →New Hope Fertility Center is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Compared within Infertility, Female, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants undergo a within-patient comparison in the same menstrual cycle. The right ovary undergoes retrieval of immature oocytes for CAPA-IVM beginning on or after menstrual cycle Day 3, before ovarian stimulation. The left ovary subsequently undergoes minimal controlled ovarian stimulation beginning on Day 5, followed by oocyte retrieval and standard IVF/ICSI. Outcomes are compared according to ovary and oocyte origin, with each participant serving as her own internal control.
Procedure: CAPA-IVM · Device: In-House CAPA-IVM Pre-Maturation Medium · Procedure: Minimal-Stimulation OS-IVF
Immature cumulus-oocyte complexes are retrieved from the right ovary before ovarian stimulation and undergo a biphasic CAPA-IVM process. The first phase is a pre-maturation/capacitation culture intended to maintain meiotic arrest while supporting developmental competence. Oocytes are then transferred to maturation conditions and assessed for maturation to metaphase II (MII). Mature oocytes may subsequently undergo ICSI and standard embryo culture according to clinical practice.
An investigational in-house reproductive culture medium is used during the pre-maturation/capacitation phase of CAPA-IVM for immature cumulus-oocyte complexes. The proprietary formulation is prepared for use in the CAPA-IVM laboratory procedure. Following the pre-maturation phase, oocytes are transferred to maturation conditions and assessed for MII maturation.
After completion of right-ovary CAPA-IVM aspiration, minimal controlled ovarian stimulation of the left ovary begins on menstrual cycle Day 5. The regimen includes clomiphene citrate for approximately 9 days and follitropin beta for approximately 3 days with ultrasound and/or hormonal monitoring. Final oocyte maturation is initiated using leuprolide acetate as a GnRH-agonist trigger. Oocytes are subsequently retrieved from the left ovary and undergo standard IVF/ICSI and embryo culture according to clinical practice.
Maturation Rate to Metaphase II (MII) Following CAPA-IVM
Proportion of immature oocytes retrieved from the CAPA-IVM ovary that reach the metaphase II (MII) stage after completion of the biphasic CAPA-IVM culture process. Maturation rate will be calculated as the number of oocytes reaching MII divided by the number of immature oocytes undergoing CAPA-IVM.
Time frame: Up to approximately 54 hours after initiation of CAPA-IVM culture
Fertilization Rate
Proportion of injected MII oocytes showing normal two-pronuclear (2PN) fertilization after ICSI, analyzed by ovary/treatment origin.
Time frame: At fertilization assessment following ICSI
Cleavage Rate
Proportion of normally fertilized embryos that undergo cleavage by embryo culture Day 2-3.
Time frame: Day 2-3 after fertilization
Blastocyst Formation Rate
Proportion of embryos developing to the blastocyst stage, analyzed according to CAPA-IVM or minimal-stimulation OS-IVF origin.
Time frame: Day 5-6 after fertilization
High-Quality Blastocyst Rate
Proportion of embryos meeting the center's predefined criteria for high-quality blastocyst morphology.
Time frame: Day 5-6 after fertilization
Clinical Pregnancy Rate
Proportion of embryo transfers resulting in a clinical pregnancy confirmed by ultrasound evidence of fetal cardiac activity.
Time frame: Approximately 7-8 weeks gestation
Ongoing Pregnancy Rate
Proportion of embryo transfers resulting in an ongoing pregnancy beyond 12 weeks gestation.
Time frame: Greater than 12 weeks gestation
Live Birth Rate
Proportion of embryo transfers resulting in a live birth. Outcomes will be analyzed according to embryo origin when traceable.
Time frame: At delivery, up to approximately 10 months after embryo transfer
Procedure-Related and Treatment-Related Adverse Events
Incidence of adverse events including ovarian hyperstimulation syndrome, egg-retrieval complications, sedation/anesthesia complications, and other study-related adverse events.
Time frame: From initiation of study treatment through 6 months after treatment
Change in Serum Anti-Müllerian Hormone (AMH)
Change in serum AMH concentration from baseline to the follow-up ovarian-reserve assessment.
Time frame: Baseline and 3-6 months after treatment
Gestational Age at Delivery
Gestational age at delivery among live-born infants resulting from embryos included in the study.
Time frame: At delivery
Change in Antral Follicle Count (AFC)
Change in antral follicle count from baseline to the follow-up ovarian-reserve assessment.
Time frame: Baseline and 3-6 months after treatment
Birth Weight
Birth weight of live-born infants resulting from embryos included in the study.
Time frame: At birth
Reported Congenital Anomalies
Number and proportion of live-born infants with one or more congenital anomalies documented at birth.
Time frame: At birth
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data are not currently planned to be made publicly available. Study results may be published or presented in aggregate form without identifying individual participants.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 5 months is below that.
Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
New Hope Fertility Center